Vertriebs- Und Verwaltungskosten Veränderung Datum
argenx SE USD 598M 181M 2026-09
AstraZeneca USD 4.07B 1.73B 2026-09
Biogen USD 752M 42.3M 2026-09
Genmab DKK 205M 39M 2026-06
Gilead Sciences USD 1.52B 70M 2026-06
GlaxoSmithKline GBP 2.16B 39M 2026-09
GRIFOLS EUR 326M 37M 2026-09
Hikma Pharmaceutical USD 288M 149M 2025-12
Incyte USD 364.27M 12.54M 2026-09
Merck EUR 1.57B 49M 2026-06
Neurocrine Biosciences USD 366.3M 16.8M 2026-09
Novartis USD 3.08B 163M 2026-09
Roche Holding CHF 6.37B 908M 2026-06
Sanofi EUR 2.31B 325M 2026-09
UCB EUR 1.47B 193M 2025-12
Vertex Pharmaceuticals USD 556.3M 25.9M 2026-09